Rupafin: second-generation antihistamine

Rupafin (rupatadine) has launched for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and adolescents.

Rupatadine is a second-generation antihistamine with selective peripheral H1-receptor antagonist activity.

Desloratadine, one of the metabolites of rupatadine, may partially contribute to the overall efficacy of the drug.

The recommended dose of Rupafin in adults is one 10mg tablet daily, taken with or without food. Rupafin is not recommended for use in children under 12 years or patients with renal or hepatic impairment. It should be used with caution in elderly patients.

View Rupafin drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases